13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001953107
Total reported value
$345.4M
$345.4M
7 檔
131.8%
During the Q4 2025 filing period, Enavate Sciences GP, LLC (CIK: 0001953107) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $345.4M across 7 reported positions.
During Q4 2025, Enavate Sciences GP, LLC performed routine portfolio adjustments (0 new buys, 1 additions, 1 trims, and 0 full exits), keeping overall allocation balanced.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZBIO | Zenas Biopharma Inc | Stock-Other | 28.08% | +7.00% | +4.20% | |
| 2 | IMNM | Immunome Inc | Stock-Other | 20.21% | -0.31% | — | |
| 3 | SION | Sionna Therapeutics Inc | Stock-Other | 20.12% | +3.30% | — | |
| 4 | UPB | Upstream Bio Inc | Stock-Other | 13.18% | -1.37% | — | |
| 5 | CMPX | Compass Therapeutics Inc | Stock-Other | 8.25% | -6.78% | — | |
| 6 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 6.49% | -0.89% | — | |
| 7 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 3.67% | -0.95% | -19.81% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IMNM | Immunome Inc | +3.2% | — | Unchanged |
| 2 | ZBIO | Zenas Biopharma Inc | +2.6% | +4.20% | Add |
| 3 | CAMP | Camp4 Therapeutics CORP | +0.2% | -19.81% | Trim |
| 4 | CMPX | Compass Therapeutics Inc | -0.1% | — | Unchanged |
| 5 | UPB | Upstream Bio Inc | -1% | — | Unchanged |
| 6 | SION | Sionna Therapeutics Inc | -2.1% | — | Unchanged |
| 7 | BBOT | Bridgebio Oncology Therapeut | -2.8% | — | Unchanged |
According to official SEC Form 13F filings, Enavate Sciences GP, LLC reported a total U.S. public equity portfolio value of $345.4M across 7 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ZBIO, IMNM, SION) accounted for 131.8% of total reported equity market value during Q4 2025.
Top Position Liquidated / Trimmed
CAMP
前期市值: $11.4M
During Q4 2025, Enavate Sciences GP, LLC's top holdings by market value included ZBIO (28.1%)、IMNM (20.2%)、SION (20.1%). The largest single position, ZBIO, represented 28.1% of total portfolio value.
In Q4 2025, Enavate Sciences GP, LLC made 2 total portfolio adjustments, initiating 0 new buys, adding to 1 positions, trimming 1 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.